Floatz logo

Myelo001

Chemotherapy-Induced Neutropenia

Myelo Therapeutics GmbHPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Chemotherapy-Induced Neutropenia cohort.

Asset / SponsorPhaseRating
Epirubicin
Myelo Therapeutics GmbH
Phase 2B
Maxy-G34
Maxygen Holdings Ltd.
Phase 2CCC

Same molecule, other indications

Myelo001 is also rated in:

myelosuppression, non-human animalDormant
B
Indicative ·
57 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →